Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan;2(1):7-14.
doi: 10.1200/JOP.2006.2.1.7.

Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer

Salvatore Ruggiero  1 , Julie Gralow, Robert E Marx, Ana O Hoff, Mark M Schubert, Joseph M Huryn, Bela Toth, Kathryn Damato, Vicente Valero
Affiliations

Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer

Salvatore Ruggiero et al. J Oncol Pract. 2006 Jan.

Abstract

Purpose: This article discusses osteonecrosis of the jaw (ONJ) and offers health care professionals practical guidelines and recommendations for the prevention, diagnosis, and management of ONJ in cancer patients receiving bisphosphonate treatment.

Methods: A panel of experts representing oral and maxillofacial surgery, oral medicine, endocrinology, and medical oncology was convened to review the literature and clinical evidence, identify risk factors for ONJ, and develop clinical guidelines for the prevention, early diagnosis, and multidisciplinary treatment of ONJ in patients with cancer. The guidelines are based on experience and have not been evaluated within the context of controlled clinical trials.

Results: ONJ is a clinical entity with many possible etiologies; historically identified risk factors include corticosteroids, chemotherapy, radiotherapy, trauma, infection, and cancer. With emerging concern for potential development of ONJ in patients receiving bisphosphonates, the panel recommends a dental examination before patients begin therapy with intravenous bisphosphonates. Dental treatments and procedures that require bone healing should be completed before initiating intravenous bisphosphonate therapy. Patients should be instructed on the importance of maintaining good oral hygiene and having regular dental assessments. For patients currently receiving bisphosphonates who require dental procedures, there is no evidence to suggest that interrupting bisphosphonate therapy will prevent or lower the risk of ONJ. Frequent clinical assessments and conservative dental management are suggested for these patients. For treatment of patients who develop ONJ, a conservative, nonsurgical approach is strongly recommended.

Conclusion: An increased awareness of the potential risk of ONJ in patients receiving bisphosphonate therapy is needed. Close coordination between the treating physician and oral surgeon and/or a dental specialist is strongly recommended in making treatment decisions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Potential mechanisms for the development of osteonecrosis of the jaw.-,-
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94–124. - PubMed
    1. Assael L. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg. 2004;62:125–126. - PubMed
    1. Schwartz HC. Osteonecrosis of the jaws: A complication of cancer chemotherapy. Head Neck Surg. 1982;4:251–253. - PubMed
    1. Sung EC, Chan SM, Sakurai K, et al. Osteonecrosis of the maxilla as a complication to chemotherapy: A case report. Spec Care Dentist. 2002;22:142–146. - PubMed
    1. Tarassoff P, Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003;61:1238–1239. - PubMed

LinkOut - more resources